International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions

Norman, R; Haas, M; Wilcken, B

International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions

Norman, R

Haas, M

Wilcken, B

Permalink

Publication Type:: Journal Article
Citation:: Health Policy, 2009, 89 (3), pp. 252 - 260
Issue Date:: 2009-03-01

Closed Access

	Filename	Description	Size
	2007003251OK.pdf		201.51 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Norman, R https://orcid.org/0000-0002-3112-3893	en_US
dc.contributor.author	Haas, M https://orcid.org/0000-0002-9726-3063	en_US
dc.contributor.author	Wilcken, B	en_US
dc.date.available	2008-08-17	en_US
dc.date.issued	2009-03-01	en_US
dc.identifier.citation	Health Policy, 2009, 89 (3), pp. 252 - 260	en_US
dc.identifier.issn	0168-8510	en_US
dc.identifier.uri	http://hdl.handle.net/10453/10369
dc.description.abstract	Objectives: To examine and evaluate the economic evidence regarding the use of tandem mass spectrometry (MS/MS) for the detection of rare metabolic conditions in neonates, and then to consider the transferability of these national-level results to other decision-making contexts. Methods: A systematic literature review was undertaken, identifying papers published between January 1997 and March 2008. Thirteen unique cost-effectiveness evaluations were identified and appraised for comparability and transferability of results across settings. Results: The primary outcome measure was usually life years gained (LYG) or quality-adjusted life years gained (QALY). The incremental cost-effectiveness ratios (ICER) presented were generally supportive of MS/MS, but showed considerable variation. Differences in assumptions made regarding prevalence and prognosis played a significant role in this variation. Conclusions: Differences in study structure, the approach to costing, the choice of intervention, control and outcome measure, and the limit of studies to developed countries makes international generalisation of the cost-effectiveness evidence difficult. The importance of assumptions regarding disease progression and subsequent health care utilisation suggests that further work needs to consider the importance of longer-term follow-up. © 2008 Elsevier Ireland Ltd. All rights reserved.	en_US
dc.relation.ispartof	Health Policy	en_US
dc.relation.isbasedon	10.1016/j.healthpol.2008.08.003	en_US
dc.subject.classification	Health Policy & Services	en_US
dc.subject.mesh	Metabolic Diseases	en_US
dc.subject.mesh	Rare Diseases	en_US
dc.subject.mesh	Internationality	en_US
dc.subject.mesh	Cost-Benefit Analysis	en_US
dc.subject.mesh	Tandem Mass Spectrometry	en_US
dc.title	International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions	en_US
dc.type	Journal Article
utslib.citation.volume	3	en_US
utslib.citation.volume	89	en_US
utslib.for	160508 Health Policy	en_US
utslib.for	1117 Public Health and Health Services	en_US
utslib.for	1605 Policy and Administration	en_US
dc.location.activity	Ireland
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Business
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
utslib.copyright.status	closed_access
pubs.issue	3	en_US
pubs.publication-status	Published	en_US
pubs.volume	89	en_US

Abstract:

Objectives: To examine and evaluate the economic evidence regarding the use of tandem mass spectrometry (MS/MS) for the detection of rare metabolic conditions in neonates, and then to consider the transferability of these national-level results to other decision-making contexts. Methods: A systematic literature review was undertaken, identifying papers published between January 1997 and March 2008. Thirteen unique cost-effectiveness evaluations were identified and appraised for comparability and transferability of results across settings. Results: The primary outcome measure was usually life years gained (LYG) or quality-adjusted life years gained (QALY). The incremental cost-effectiveness ratios (ICER) presented were generally supportive of MS/MS, but showed considerable variation. Differences in assumptions made regarding prevalence and prognosis played a significant role in this variation. Conclusions: Differences in study structure, the approach to costing, the choice of intervention, control and outcome measure, and the limit of studies to developed countries makes international generalisation of the cost-effectiveness evidence difficult. The importance of assumptions regarding disease progression and subsequent health care utilisation suggests that further work needs to consider the importance of longer-term follow-up. © 2008 Elsevier Ireland Ltd. All rights reserved.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/10369